Advanced Life Sciences Holdings, Inc. (NASDAQ: ADLS), a biopharmaceutical company, is focused discovering, developing, and commercializing novel drugs in the therapeutic areas of respiratory diseases, infection, and cancer. Cethromycin, the Company’s lead candidate, is a novel NDA-stage once-a-day oral antibiotic designed to treat respiratory tract infections, such as pneumonia. For further information, visit the Company’s web site at www.advancedlifesciences.com.
- 18 years ago
QualityStocks
Advanced Life Sciences Holdings, Inc. (NASDAQ: ADLS)
Tags Rodman & Renshaw
Related Post
-
QualityStocksNewsBreaks – Regentis Biomaterials Ltd. (NYSE American: RGNT) Moves GelrinC Closer to Regulatory and Commercial Milestones
Regentis Biomaterials (NYSE American: RGNT) is advancing its GelrinC hydrogel-based cartilage regeneration technology toward key clinical, regulatory…
-
Wrap Technologies Inc. (NASDAQ: WRAP) Positions Non-Lethal Innovation at the Center of Public Safety Reform
WRAP offerings illustrate a broader industry trend toward building connected ecosystems rather than standalone products.…
-
Brownfield Gold Projects Could Hold an Edge in Today’s Permitting Environment
Disseminated on behalf of Lahontan Gold Corp. (TSX.V: LG) (OTCQB: LGCXF) and may include paid advertising.…